Perfluorinated Compounds (PFAS) vs Red Dye 3: which is worse?

What is Perfluorinated Compounds (PFAS)?

Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemicals characterized by extremely strong carbon-fluorine bonds. They are used in food packaging (grease-resistant coatings), non-stick cookware (PTFE/Teflon), food processing equipment, firefighting foam, and many industrial applications. The 'forever chemicals' moniker reflects their extreme environmental persistence.

What is Red Dye 3?

Red Dye 3 (erythrosine) is a synthetic cherry-pink fluorescent dye belonging to the xanthene class. It contains approximately 58% iodine by weight, distinguishing it from azo dyes. Its chemical formula is C20H6I4Na2O5. Approved since 1907, it is one of the oldest certified US food colorants and was notably the first synthetic food dye formally revoked by the FDA in decades.

Documented risks

Perfluorinated Compounds (PFAS): PFAS are among the most extensively studied and harmful groups of synthetic chemicals in the modern environment. Their unique carbon-fluorine bond stability means they do not break down in the environment or in human body tissues — contributing to bioaccumulation over a lifetime. Health effects documented in human epidemiological studies include: - Cancer: PFOA (perfluorooctanoic acid) and PFOS (perfluorooctanesulfonic acid) have been associated with kidney cancer, testicular cancer, thyroid cancer, bladder cancer, and non-Hodgkin lymphoma in occupationally exposed workers and community members with contaminated drinking water. IARC classified PFOA as Group 1 (human carcinogen) in 2023 and PFOS as Group 2B. - Endocrine disruption: PFAS disrupt thyroid hormone signaling and sex hormone balance. Multiple studies find associations between PFAS exposure and hypothyroidism, early puberty in girls, and reduced sperm quality. - Immune suppression: studies have found that PFAS exposure is associated with reduced vaccine response in children and adults, suggesting PFAS may impair immune function. - Developmental effects: prenatal PFAS exposure has been associated with lower birth weight, developmental delays, and reduced immune response in infants. - Cholesterol: PFAS exposure consistently raises LDL cholesterol levels, increasing cardiovascular disease risk. The 2023 EPA MCLG (maximum contaminant level goal) for PFOA and PFOS is zero — reflecting the agency's conclusion that there is no safe level. The EPA set enforceable MCLs in drinking water in 2024. The DuPont/3M PFOA/PFOS contamination of drinking water in communities near Teflon manufacturing facilities led to a $671 million settlement (DuPont/Chemours, 2017) and $10.3 billion 3M settlement (2023) — among the largest environmental contamination settlements in history.

Red Dye 3: The FDA revoked Red Dye 3 authorization in January 2025, marking the first synthetic food dye ban by the FDA since Red Dye 2 in 1976. The revocation was triggered by the Delaney Clause, which mandates revocation of any food additive found to cause cancer in animals regardless of dose. The carcinogenicity data stems from studies showing that high doses of erythrosine caused thyroid follicular cell tumors in male rats. The mechanism is indirect: erythrosine suppresses thyroid-stimulating hormone (TSH) feedback by elevating thyroxine (T4) levels, causing chronic TSH suppression that promotes thyroid cell proliferation and ultimately tumor formation. This is a rat-specific mechanism related to their thyroxine-binding protein system, which differs from human biology. EFSA's 2011 comprehensive safety assessment concluded erythrosine was unlikely to be genotoxic at typical food use levels and set an ADI of 0.1 mg/kg body weight — one of the lowest for any food color. EFSA restricted EU use to cocktail cherries only (max 200 mg/kg). The high iodine content (58% by weight) raises concerns for thyroid-sensitive individuals. Excessive erythrosine intake could theoretically contribute to iodine overload and thyroid disruption, particularly in individuals with hyperthyroidism or Hashimoto's disease. The FDA had been aware of the rat thyroid tumor data since 1990 but delayed action for 35 years. Advocacy groups including CSPI petitioned for a ban since 1983. The January 2025 revocation finally addressed this long-standing regulatory gap.